Ado-trastuzumab Emtansine Therapy for HER2-Mutant or Amplified Lung Cancers
Results from a phase II basket trial, presented at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 14.05) in Yokohama, Japan, found that ado-trastuzumab emtansine (formerly known as T-DM1) is well tolerated in patients with HER2-mutant or amplified lung cancers. Primary investigator, Bob T. Li, MD, MPH, of Memorial Sloan Kettering Cancer Center, remarked in an IASLC press release: “This highlights the message that those patients can benefit from a new HER2 antibody-drug conjugate, and future clinical trials of HER2-targeted agents should not exclude these patients.” Cohort expansion is ongoing to explore this therapy further in this patient population.
The investigators identified 33 patients for enrollment by next-generation sequencing. In the HER2-mutant cohort, 18 patients were accrued, and the overall response rate was 44% in this group. The median progression-free survival was 4 months for this group and 6 months for responders. In the positron-emission tomography response criteria in solid tumors–measured HER2-mutant cohort of nine patients, two confirmed partial responses of the five patients evaluated were reported. In the HER2-amplified cohort of six patients, three partial responses were confirmed; one of the responders had concurrent epidermal growth factor receptor (EGFR)-sensitizing mutation and resistance to erlotinib.